Notably, inhibition of xCT selectively kills KRAS-mutant cancer cells in vitro and strongly attenuates oncogenic RAS transformation in xenograft models, highlighting an unappreciated function of the antioxidant program to RAS-driven tumourigenesis [39, 45]. The gene discussed is KRAS; the disease is cancer.